Telemonitoring - Compliance Measuring in case of cystic fibrosis therapy
Under the supervision of the Hannover Medical School, Dr. med. Manfred Ballmann, Center for paediatrics, paediatric pneumology and neonatology, started a first project implementing the use of telemonitoring systems to support inhalation therapy of cystic fibrosis in January 2010. Included over the course of 15 months were 80 adolescents and children between four and eight years suffering from cystic fibrosis.
Cystic fibrosis is a hereditary, autosomal-recessive metabolic disease, in which the buildup of mucus in the bronchial system causes chronic cough, bronchiectasis, and repeated lung infections and heavy inflammation. Result of these frequent and long lasting lung infections are increasing lung insufficiency, noticeable by chronic hyperoxia and breathing difficulty.
Project overview - telemonitoring in case of cystic fibrosis therapy
Improving therapy by measuring and control
Common cystic fibrosis treatment is inhalation therapy using a nebulizer. Compliance of diseased children and adolescents is important, in this case regular inhalation with the prescribed medication. To realize this project, Aipermon installed Bluetooth to eFlow inhalation nebulizers from the Pari company. At every use of the inhalation nebulizer, duration and time of inhalation are transferred to a MMA 400 – a PDA device specially modified by Aipermon for data transfer – as well as to the Aipermon Service Center and the Hannover Medical School. Here, data is stored and analyzed in terms of therapy compliance.
Project aim
Aim of this randomized and controlled clinical study is firstly the measuring of therapy compliance of diseased children and adolescents and secondly an increase in compliance.
